X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (15) 15
humans (14) 14
hematology (12) 12
female (9) 9
male (9) 9
aged (8) 8
middle aged (8) 8
oncology (8) 8
rituximab (8) 8
leukemia (7) 7
leukemia, lymphocytic, chronic, b-cell - drug therapy (7) 7
activation (6) 6
aged, 80 and over (6) 6
antineoplastic combined chemotherapy protocols - therapeutic use (6) 6
cancer (6) 6
antineoplastic combined chemotherapy protocols - adverse effects (5) 5
care and treatment (5) 5
life sciences (5) 5
mutation (5) 5
survival (5) 5
treatment outcome (5) 5
antineoplastic agents - therapeutic use (4) 4
chronic lymphocytic leukemia (4) 4
chronic lymphocytic-leukemia (4) 4
cyclophosphamide (4) 4
research (4) 4
retrospective studies (4) 4
[sdv.mhep.hem]life sciences [q-bio]/human health and pathology/hematology (3) 3
adult (3) 3
analysis (3) 3
antibodies, monoclonal, murine-derived - administration & dosage (3) 3
cll (3) 3
cyclophosphamide - administration & dosage (3) 3
disease-free survival (3) 3
drug resistance (3) 3
human health and pathology (3) 3
immunotherapy (3) 3
leukemia, lymphocytic, chronic, b-cell - mortality (3) 3
patients (3) 3
abridged index medicus (2) 2
age factors (2) 2
aged patients (2) 2
animals (2) 2
antibodies, monoclonal - therapeutic use (2) 2
antibodies, monoclonal, murine-derived - therapeutic use (2) 2
antineoplastic agents - adverse effects (2) 2
antineoplastic agents - pharmacology (2) 2
blood platelets - drug effects (2) 2
cell biology (2) 2
chemoimmunotherapy (2) 2
chemotherapy (2) 2
chronic lymphatic leukemia (2) 2
cohort studies (2) 2
collagen (2) 2
cytogenetics (2) 2
diagnosis (2) 2
elderly-patients (2) 2
fludarabine (2) 2
follicular lymphoma (2) 2
genetic aspects (2) 2
glycogen (2) 2
health aspects (2) 2
hematology, oncology and palliative medicine (2) 2
hemic and lymphatic diseases (2) 2
ighv (2) 2
immunoglobulin heavy chains - genetics (2) 2
immunology (2) 2
kinases (2) 2
leukemia, lymphocytic, chronic, b-cell - diagnosis (2) 2
leukemia, lymphocytic, chronic, b-cell - genetics (2) 2
lymphatic leukemia (2) 2
lymphocytic leukemia (2) 2
lymphoma, large b-cell, diffuse - drug therapy (2) 2
lymphomas (2) 2
malignancies (2) 2
medical prognosis (2) 2
medical research (2) 2
medicine, experimental (2) 2
neutropenia - chemically induced (2) 2
non-hodgkin's lymphomas (2) 2
non-hodgkins-lymphoma (2) 2
outcomes (2) 2
p53 protein (2) 2
phosphorylation (2) 2
prognosis (2) 2
protein kinase inhibitors - therapeutic use (2) 2
risk stratification (2) 2
survival analysis (2) 2
targeting btk (2) 2
therapy (2) 2
thrombus stability (2) 2
time factors (2) 2
tp53 (2) 2
trisomy (2) 2
tumor proteins (2) 2
vidarabine - administration & dosage (2) 2
vidarabine - analogs & derivatives (2) 2
14q deletions (1) 1
17p deletion (1) 1
1st-line treatment (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 6, pp. 525 - 533
Journal Article
Lancet Haematology, The, ISSN 2352-3026, 2017, Volume 4, Issue 3, pp. e114 - e126
Journal Article
PLoS ONE, ISSN 1932-6203, 2010, Volume 5, Issue 3, p. e9807
Background Cell survival mediated by integrin engagement has been implicated in cell adhesion-mediated drug resistance. We have recently demonstrated that the... 
Phosphorylation | Starvation | Cell survival | Laboratories | Glycogen | Leukemia | Chemoresistance | Glycogen synthase kinase 3 | Activation | Insulin-like growth factors | Dephosphorylation | Tumor necrosis factor-α | Drug resistance | Kinases | Survival | Cytosol | Fibronectin | Cell adhesion & migration | Scaffolding | Cell lines | Cell adhesion | Apoptosis
Journal Article
Leukemia Research, ISSN 0145-2126, 10/2019, Volume 85, p. 106199
Journal Article
HAEMATOLOGICA, ISSN 0390-6078, 10/2019, Volume 104, Issue 11, pp. 2292 - 2299
While efficient at treating B-cell malignancies, Bruton tyrosine kinase (BTK) inhibitors are consistently reported to increase the risk of bleeding. Analyzing... 
UNITED-STATES | BRUTONS TYROSINE KINASE | ACTIVATION | COLLAGEN | X-LINKED AGAMMAGLOBULINEMIA | ACP-196 | ABSENCE | INHIBITORS | TARGETING BTK | HEMATOLOGY | THROMBUS STABILITY
Journal Article
Genes, Chromosomes and Cancer, ISSN 1045-2257, 11/2018, Volume 57, Issue 11, pp. 533 - 540
Journal Article
Hematological Oncology, ISSN 0278-0232, 12/2017, Volume 35, Issue 4, pp. 664 - 670
Journal Article
Journal of Immunology, ISSN 0022-1767, 10/2013, Volume 191, Issue 7, pp. 3634 - 3640
Journal Article
OncoImmunology, ISSN 2162-4011, 03/2019, Volume 8, Issue 3, p. 1554175
Follicular lymphoma (FL) is a common non Hodgkin's lymphoma subtype in which immune escape mechanisms are implicated in resistance to chemo-immunotherapy.... 
anti-CD20 MAbs | 3D model | γδ T cells | follicular lymphoma | PD-1 | Life Sciences | Immunology | Cancer
Journal Article
Blood, ISSN 0006-4971, 12/2016, Volume 128, Issue 22, pp. 3242 - 3242
Abstract Introduction Atrial fibrillation (AF) occurs in 5-9% of patients treated with ibrutinib for CLL. We previously reported on the clinical... 
Journal Article
Leukemia & Lymphoma, ISSN 1042-8194, 03/2012, Volume 53, Issue 3, pp. 362 - 370
Abstract The introduction of purine nucleoside analogs, later in combination with alkylating moieties and anti-CD20 immunotherapy, has profoundly improved the... 
Immunotherapy | lymphoid leukemia | antibody-based immunotherapy | Lymphoid leukemia | Antibody-based immunotherapy | 1ST-LINE TREATMENT | CD20 EXPRESSION | MAINTENANCE TREATMENT | PREVIOUSLY UNTREATED PATIENTS | PHASE-III TRIAL | SUBCUTANEOUS ALEMTUZUMAB | ONCOLOGY | INITIAL THERAPY | STEM-CELL TRANSPLANTATION | MONOCLONAL-ANTIBODIES | HEMATOLOGY | CLINICAL ACTIVITY | Cyclophosphamide - administration & dosage | Humans | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Antineoplastic Agents - therapeutic use | Cyclophosphamide - adverse effects | Cyclophosphamide - therapeutic use | Agammaglobulinemia - chemically induced | Neutropenia - chemically induced | Antibodies, Monoclonal, Humanized - adverse effects | Antigens, CD20 - immunology | Antibodies, Monoclonal, Humanized - therapeutic use | Vidarabine - adverse effects | Rituximab | Treatment Outcome | Vidarabine - analogs & derivatives | Alemtuzumab | Vidarabine - therapeutic use | Remission Induction | Leukemia, Lymphocytic, Chronic, B-Cell - pathology | Disease-Free Survival | Leukemia, Lymphocytic, Chronic, B-Cell - therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Neoplasm, Residual - drug therapy | Vidarabine - administration & dosage | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Antibodies, Monoclonal, Murine-Derived - adverse effects | Antibodies, Monoclonal, Murine-Derived - therapeutic use
Journal Article
Leukemia, ISSN 0887-6924, 2019, Volume 33, Issue 11, pp. 2654 - 2661
A staging system was developed a decade ago for patients with Waldenström’s macroglobulinemia (WM), however, since then WM treatments have changed. A revised... 
Medical prognosis | Rituximab | Risk | Serum albumin | Patients | b2-microglobulin | Macroglobulinemia
Journal Article
British Journal of Haematology, ISSN 0007-1048, 11/2016, Volume 175, Issue 3, pp. 462 - 466
Journal Article